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Abstract
Background—Widespread use of the HPV vaccine has the potential to reduce incidence from 
HPV-associated cancers. However, vaccine uptake among adolescents remains well below the 
Healthy People 2020 targets. The Centers for Disease Control and Prevention (CDC)’s National 
Comprehensive Cancer Control Program awardees (NCCCP) are well positioned to work with 
immunization programs to increase vaccine uptake.
Methods—CDC’s chronic disease management information system was queried for objectives 
and activities associated with HPV vaccine that were reported by NCCCP awardees from 2013 – 
2016 as part of program reporting requirements. A content analysis was conducted on the query 
results to categorize interventions according to strategies outlined in The Guide to Community 
Preventive Services and the 2014 President’s Cancer Panel report.
Results—Sixty-two percent of NCCCP awardees had planned or implemented at least one 
activity since 2013 to address low HPV vaccination coverage in their jurisdictions. Most NCCCP 
awardees (86%) reported community education activities, while 65% reported activities associated 
with provider education. Systems-based strategies such as client reminders or provider assessment 
and feedback were each reported by less than 25% of NCCCP awardees.
Conclusion—Many NCCCP awardees report planning or implementing activities to address low 
HPV vaccination coverage, often in conjunction with state immunization programs. NCCCP 
awardees can play a role in increasing HPV vaccination coverage through their cancer prevention 
and control expertise and access to partners in the health care community.
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Introduction
Over 10 years have passed since the first human papilloma virus (HPV) vaccine was 
licensed and recommended by the Advisory Council for Immunization Practices (ACIP) in 
the United States to prevent cervical cancer and other HPV-related outcomes.1 Vaccine 
uptake for adolescent girls and boys aged 13 – 17 years lags behind those for other 
adolescent vaccines such as vaccines for tetanus, diphtheria, and pertussis; and 
meningococcal meningitis.2 In 2015, only about 42% of adolescent girls and 28% of 
adolescent boys had received all three HPV vaccine doses recommended, while coverage 
with one or more vaccine doses was 63% for adolescent girls and nearly 50% for adolescent 
boys.2 Coverage for adolescent boys lags behind girls because ACIP did not recommend 
routine vaccination of boys until 2011.3
Nearly 31,000 newly diagnosed cancer cases each year may be attributable to any HPV type.
4
 Fewer cases are diagnosed in men, but they experience a greater burden of oropharyngeal 
cancers each year than women.4 Among women, cervical cancer is the leading HPV-
attributable cancer, followed by anal, vulvar, oropharyngeal, vaginal, and rectal cancers.4 
Overall, nearly 12,000 women are diagnosed each year with cervical cancer, and over 4,000 
women die of the disease.5 Although screening for cervical cancer using the Papanicolaou 
(Pap) test has dramatically reduced the cervical cancer burden in the US over the past several 
decades, over half of cervical cancer cases are among women who have never or rarely been 
screened.6–8 Cervical cancer rates also vary by race/ethnicity and other demographic factors, 
and tend to be highest for Hispanic and African American women and women living in the 
southern US.4, 5 Widespread use of the HPV vaccine has the potential to reduce incidence 
and mortality from HPV-associated cancers, and narrow absolute differences in HPV-
associated cancer incidence rates among Hispanic and African American women compared 
to non-Hispanic white women.9
In recent years, the Centers for Disease Control and Prevention (CDC) has worked to raise 
awareness of persistently low HPV vaccine uptake and address some of the issues that 
research has identified as contributing to low vaccine uptake, such as the lack of a strong 
recommendation by many health care providers or a risk-based approach toward 
vaccination; lack of awareness by parents and concerns about vaccine safety, or a desire to 
delay vaccination until older adolescence; and missed opportunities to administer the 
vaccine.10–16 The 2014 President’s Cancer Panel Report17 highlighted similar barriers to 
HPV vaccine uptake, and provided several key goals and objectives to focus intervention 
efforts as a way to accelerate vaccine uptake. These initiatives have brought about 
prioritization of HPV vaccine interventions and new opportunities for collaboration across 
CDC and among other government agencies and organizations. One example includes 
collaboration between CDC’s National Comprehensive Cancer Control Program (NCCCP) 
and the National Center for Immunization and Respiratory Diseases (NCIRD).
CDC’s NCCCP funds all 50 states, the District of Columbia, seven tribes/tribal 
organizations, and 7 Pacific Island Jurisdictions and territories for comprehensive cancer 
control (CCC) activities (http://www.cdc.gov/cancer/ncccp/index.htm). Priorities of the 
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NCCCP include primary prevention, secondary prevention and screening, and cancer 
survivorship, along with cross-cutting areas that include health equity, data and evaluation, 
and policy, systems, and environmental change approaches (http://www.cdc.gov/cancer/
ncccp/about.htm). The CCC approach is built on the premise that bringing together cancer 
control stakeholders to collectively address the cancer burden in a jurisdiction creates 
synergy and allows for the leveraging of resources.18 NCCCP awardees create and 
implement data-informed cancer plans in collaboration with their CCC coalition or 
partnership. CCC coalition partners often include academic and medical partners, health 
systems, community-based organizations, businesses, other governmental organizations, and 
other health department divisions, such as NCIRD awardees. NCIRD provides funding to all 
50 states, the District of Columbia, eight Pacific Island Jurisdictions and other territories, 
and selected city health departments (http://www.cdc.gov/vaccines/imz-managers/awardee-
imz-websites.html) to administer the Vaccines for Children program, section 317 
immunization grants, support immunization information systems, provide training and 
education to health professionals, and improve the uptake and delivery of vaccines.
Some awardees of both the NCIRD and NCCCP have worked together to add an objective to 
jurisdictional cancer plans about implementing interventions to promote HPV vaccine 
uptake. The purposes of this report are to identify which NCCCP awardees have recently 
been involved in interventions to promote HPV vaccine uptake and to describe the types of 
interventions they have implemented. This knowledge will help identify which intervention 
areas NCCCP awardees can be most effective in implementing and identify areas of the US 
in which collaboration between NCIRD and NCCCP awardees could be enhanced to address 
the burden of HPV-associated cancers.
Materials and Methods
Data source and search strategy
We queried CDC’s Web-based chronic disease management information system (CDMIS) 
for NCCCP awardee action plans containing objectives, interventions, or activities to 
promote uptake of HPV vaccine (http://www.cdc.gov/cdmis/index.html). CDMIS is a secure 
government system that meets all federal requirements and approvals for public data 
collection (OMB #0920-0841). CDMIS collects detailed information on priority objectives 
and interventions included in an action plan section. The action plan is a requirement of the 
cooperative agreement, and describes program implementation within a given budget year. 
All NCCCP awardees complete action plans each year that contain the long-term (i.e. five 
year) objectives in their cancer plans, annual objectives to achieve the five-year ones, and 
activities to achieve the annual objectives. NCCCP awardees are also required to report 
progress on objectives as a condition of funding. The terms “HPV and vaccination” or “HPV 
and vaccine” were used to conduct key word searches. We also searched for the terms 
“vaccination: HPV” or “immunization,” which are associated with long-term objectives. To 
coincide with the most recent funding period (2012 – 2017) and to capture more current 
HPV vaccine activities, we limited our queries to the time period covering 2013 – 2016, 
which represents the full programmatic implementation phase.
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Data analysis
We downloaded the query results into Microsoft Excel for further qualitative content 
analyses. We removed content from the analysis that did not pertain to planning or 
implementation of activities or interventions for promoting HPV vaccine use. We developed 
a codebook to assist with coding HPV vaccine content according to the Guide for 
Community Preventive Services (The Community Guide) strategies for increasing 
vaccination coverage, and other categories associated with common public health activities 
in the NCCCP (e.g. planning interventions or convening partners). Content was also coded 
according to priority areas identified in the 2014 President’s Cancer Panel Report, and we 
developed code definitions based on the strategies outlined within the priority areas. We 
reviewed each objective and associated text fields describing the public health impact of the 
objective, as well as narrative descriptions of progress toward meeting the objective and the 
types of activities or partners involved. We coded multi-component interventions to multiple 
categories, and many programs conducted intervention planning prior to implementation 
over the time period. In some instances, objectives required more information in order to 
properly categorize the specific strategy or intervention. Therefore, we reviewed products 
(e.g., PowerPoint presentations, fact sheets, toolkits) uploaded to CDMIS, or appearing 
either on the NCCCP awardee’s or their coalition’s website. SAS version 9 (SAS Institute 
Inc., Cary, NC) was used to calculate frequency counts and percentages for each coded 
category.
Data visualization
In order to provide local context for initiatives undertaken by NCCCP awardees, HPV 
vaccination coverage and the burden of cervical cancer (most are attributed to HPV) was 
downloaded from the National Immunization Survey (NIS)-Teen and the United States 
Cancer Statistics (USCS), respectively. Vaccine coverage with one or more doses among 
adolescent females aged 13 – 17 in 2015,2 and cervical cancer incidence rates among 
women of all ages from 2009 – 2013 were downloaded from these sources.19 We created 
maps in ArcGIS software (Esri, Redlands, CA) to show 1) adolescent female HPV 
vaccination coverage and 2) cervical cancer incidence rates among all women; both were 
layered with information about NCCCP awardees implementing HPV-related interventions.
Results
Overall, 62% of all NCCCP awardees had planned or implemented at least one activity since 
2013 to address low HPV vaccination coverage (Table 1). NCCCP awardees in the Midwest 
more frequently reported HPV vaccine activities and interventions (28%), followed by those 
in the South (23%, Table 1). Although most activities were reported by states, eight tribal 
organizations and Pacific Island Jurisdictions/territories also engaged in HPV-related 
activities (Table 1).
The majority of NCCCP awardees (86%) reported engaging in activities to educate the 
community, particularly parents, about the need for HPV vaccine (Table 1). Sixty-five 
percent of NCCCP awardees reported activities associated with provider education. 
Intervention planning before implementing interventions was reported by 44% of NCCCP 
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awardees at some point during the time period. Relatively fewer awardees reported 
interventions that addressed provider reminders (7%), provider assessment and feedback or 
quality assurance (23%), client reminders (19%), or school-based vaccination (12%). Most 
NCCCP awardees used multiple strategies to conduct HPV interventions.
Nearly all NCCCP awardees engaged in HPV-related work reported interventions or 
activities that aligned with increasing vaccine acceptance (86%, Table 2). Over half of those 
described activities to address missed opportunities for vaccination (56%), and few reported 
interventions to maximize access to vaccination (23%). Examples of activities to increase 
vaccine acceptance included comprehensive media or communications campaigns, and 
training school nurses to provide education to parents or students about the vaccine. 
Interventions focused on reducing missed opportunities to vaccinate included provider 
education on making a strong vaccine recommendation to parents, and minimizing other 
missed opportunities to provide the vaccine by co-administering it with other adolescent 
vaccines, and taking advantage of other clinical encounters, such as sports physicals or back-
to-school checkups. Some NCCCP awardees described efforts to implement client reminder 
systems within partner health systems or insurance companies, or through the state 
immunization information system. Provider reminder systems were another intervention to 
reduce missed opportunities. Examples of interventions to maximize access to vaccination 
services included school-based vaccination clinics, and educating college students about the 
HPV vaccine and its availability in the college health clinic.
Engagement in HPV-related activities was not entirely dependent on vaccination coverage 
(Figure 1) or cervical cancer incidence rates (Figure 2). Several NCCCP awardees within 
states that have relatively high HPV vaccination coverage for the first dose among 
adolescent females and those with the lowest coverage engaged in HPV-related activities 
(Figure 1). Although a number of NCCCP awardees in states with comparatively higher 
cervical cancer incidence rates reported activities to increase HPV vaccination coverage, 
some states with similarly high rates did not have any HPV-related activities (Figure 2).
Discussion
Objectives and activities to increase HPV vaccine uptake were common in NCCCP 
awardees’ action plans over the 2013 – 2016 time period. These activities coincided with a 
large national effort to increase HPV vaccine uptake, as well as new funding opportunities to 
promote HPV vaccine, such as through Prevention and Public Health Funding (PPHF) for 
select immunization programs (https://pphf.hhs.gov/jsp/about.jsp). NCCCP awardees in 
states with PPHF-funded immunization programs more frequently reported multicomponent 
strategies, such as both public and provider education, and strategies directed at systems 
change (e.g. routine use of client reminders). However, some NCCCP awardees relied on 
either community education or provider education alone as a strategy, neither of which are 
recommended by The Community Guide as single intervention strategies due to insufficient 
evidence of effectiveness.20 Although large scale media campaigns can result in a temporary 
increase in vaccination coverage rates, they may not result in sustained progress.21 However, 
some recent studies have found patient education implemented alone in community settings 
to be effective at increasing coverage for HPV vaccine and series completion.22–24
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NCCCP awardees frequently reported planning interventions in collaboration with 
immunization programs. Increasingly, partnerships are critical in public health to 
successfully implement and sustain interventions. In the Six Components Necessary for 
Effective Public Health Program Implementation, partnerships are identified as a key 
component of implementation.25 When partnership building is successful and done through 
a mutually beneficial approach with shared vision and goals and collaborative decision-
making, then synergy can arise for sustainable interventions.26–28 Practically speaking, the 
right partners can bring expertise, resources (e.g. financial, donated staff time), and 
connections to other partners and sectors. In the case of efforts to increase HPV vaccine 
uptake, NCCCP awardees are logical partners for immunization programs not only because 
of the cancer prevention focus of the vaccine, but because they have connections to cancer 
coalitions that includes additional partners in the cancer community who can bring expertise 
and new avenues for interventions.
These findings reveal that some NCCCP awardees in states with historically low HPV 
vaccination coverage, such as Alaska, Kansas, New Jersey, and Tennessee, are implementing 
activities such as community or provider education.29 In some instances, states with low 
HPV vaccination coverage are also states with high cervical cancer incidence and mortality, 
so directing public health efforts toward this area may be a strategic way to address the 
burden of cervical cancer and other HPV-associated cancers. For example, HPV vaccination 
coverage is typically lower in the South while cervical cancer incidence and death rates are 
higher in this geographic area compared to other US regions; therefore, encouraging 
NCCCP awardees in southern states to implement interventions may be a promising strategy 
to lower incidence and death rates.29, 30 However, some states with high cervical cancer 
burden reported no interventions to increase HPV vaccine uptake, representing a missed 
opportunity to further reduce disparities for a preventable disease.31 Rates of HPV vaccine 
initiation do tend to be higher among Hispanic and African American adolescent girls, and 
adolescents of lower socioeconomic status, so ensuring these adolescents receive timely 
reminders to complete the vaccination series may reduce existing cervical cancer disparities.
2
 Thus, sustained, multicomponent interventions utilizing immunization and cancer control 
partners may have the most impact over time.20, 22
In recent years, NCIRD has developed numerous resources to promote HPV vaccine that are 
directed to both providers and parents of adolescents (http://www.cdc.gov/hpv/). Provider 
resources include You are the Key to HPV Cancer Prevention continuing education series, 
factsheets, posters, and other resources (e.g. radio PSAs and video content). Resources were 
also developed to engage with HPV vaccination partners, including an HPV Vaccination 
Partner Toolkit that includes print materials, video and audio content, information on quality 
improvement and evidence-based interventions, and ideas for developing partner networks 
and engaging local partners.
Resources from other national efforts have supported NCCCP awardees to implement 
interventions along with their immunization partners. The CCC National Partners (http://
www.cccnationalpartners.org/), which also include the National Cancer Institute (NCI) and 
the American Cancer Society (ACS), have prioritized promoting HPV vaccine. NCI has 
funded comprehensive cancer centers to conduct an environmental scan of HPV vaccine 
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activities in their states, and to enhance linkages with coalitions and immunization and 
cancer control programs in their areas (http://healthcaredelivery.cancer.gov/hpvuptake/). 
CDC’s Division of Cancer Prevention and Control (DCPC) and the Immunization Services 
Division funded the ACS to develop and administer the National HPV Vaccination 
Roundtable (http://www.cancer.org/healthy/informationforhealthcareprofessionals/
nationalhpvvaccinationroundtable/), a coalition of public, private, and voluntary 
organizations with expertise relevant to increasing HPV vaccination coverage in the US, as a 
way to reduce illness and death from HPV-associated cancers, through coordinated 
leadership, strategic planning, and advocacy. Finally, CDC’s DCPC has funded and 
administered a national educational awareness campaign since 2009, Inside Knowledge: Get 
the Facts About Gynecologic Cancer, which includes specific messages on HPV vaccination 
as prevention for cervical, vaginal, and vulvar cancers.32
Our study has limitations. We relied on data reported by the program director or an 
individual or individuals to complete the tasks. NCCCP awardees vary in providing details 
that describe their activities and interventions; therefore, some interventions may not have 
been accurately classified because of data limitations. Additionally, not all NCCCP awardees 
with HPV vaccine-related interventions reported them for each year in our study period, and 
most systems-based interventions or interventions to maximize access to HPV vaccine were 
limited to a few local areas or provider practices and were not implemented population wide. 
In terms of the data search strategy, we focused on the most common terms that would yield 
relevant content; this could have limited our system’s search capabilities to capture all 
related interventions. Also, the use of one reviewer to review and code content may have 
been a limitation; however, the straightforward nature of this analysis has allowed for 
successful coding with one reviewer in previous similar studies using this data source.33, 34 
One strength of our study is that CDMIS allows for current monitoring of activities and 
objectives which are captured in a fairly standardized manner.
Conclusion
It is advantageous for immunization programs and NCCCP awardees to collaborate on the 
goal of increasing HPV vaccine uptake. NCCCP awardees can leverage their network of 
partners and coalition members to plan activities, disseminate information, and implement 
interventions. It may be useful to define specific roles for NCCCP awardees, particularly in 
implementing multicomponent interventions, to avoid duplication of effort. While working 
in the vaccine arena, NCCCP awardees may have challenges, such as parental concerns 
about vaccine safety or early initiation of sexual activity among their children if they get 
vaccinated, or resistance by management or stakeholders who may not see the value in 
promoting HPV vaccine. Regular training by national organizations and ongoing dialogue 
with immunization partners about how to best address emerging issues may be helpful in 
these areas. NCCCP awardees in areas with a high cervical cancer burden may want to 
consider implementing multicomponent HPV vaccine interventions that include client 
reminders or provider assessment and feedback, and evaluate promising practices such as 
offering catchup HPV vaccination or systems changes that include adding the HPV vaccine 
to lists of recommended adolescent vaccines that may be provided by school nurses, athletic 
departments or camps. The goal is to raise HPV vaccination coverage to the level of other 
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adolescent vaccines, and normalize HPV vaccine as a routine adolescent vaccine. NCCCP 
awardees can play a role through their cancer prevention and control expertise and access to 
partners in the health care community.
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Figure 1. 
Vaccination coverage with 1 or more doses of HPV vaccine among adolescent females aged 
13 – 17 years and state Comprehensive Cancer Control Programs implementing activities to 
promote HPV vaccination. Note: HPV vaccination coverage data are from the 2015 National 
Immunization Survey – Teen. State National Comprehensive Cancer Control Program 
(NCCCP) awardees reporting activities to promote HPV vaccination are noted with yellow 
dots. Not shown on the map are five United States-affiliated Pacific Island Jurisdictions and 
other territories and three Tribal Nations and organizations who reported activities. 
Activities were reported by 43 out of 69 (62%) of NCCCP awardees.
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Figure 2. 
Cervical cancer incidence rates among women of all ages from 2009 – 2013 and state 
Comprehensive Cancer Control Programs implementing activities to promote HPV 
vaccination. Note: Cervical cancer incidence rates are per 100,000 population and age-
adjusted to the 2000 US standard population (19 age groups: <1, 1 – 4, 5 – 9,…, 80 – 84, 
85+). Data source: CDC's National Program of Cancer Registries Cancer Surveillance 
System (NPCR-CSS) November 2015 data submission and the National Cancer Institute's 
Surveillance, Epidemiology, and End Results (SEER) Program November 2015 submission 
as published in United States Cancer Statistics. Data are available at https://
www.statecancerprofiles.cancer.gov/index.html.
State National Comprehensive Cancer Control Program (NCCCP) awardees reporting 
activities to promote HPV vaccination are noted with yellow dots. Not shown on the map are 
five United States-affiliated Pacific Island Jurisdictions and other territories and three Tribal 
Nations and organizations who reported activities. Activities were reported by 43 out of 69 
(62%) of NCCCP awardees.
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Table 1
Characteristics of Comprehensive Cancer Control Programs with HPV vaccine objectives or interventions in 
their action plans, 2013 – 2016
Characteristic Number of Programs (%)
One or more objectives or interventions to promote HPV vaccination 43 (62.3)
Jurisdictional setting
State 35 (81.4)
Territory/Pacific Island Jurisdiction 5 (11.6)
Tribe/Tribal Organization 3 (7.0)
Census region
Northeast 7 (16.3)
Midwest 12 (27.9)
South 10 (23.3)
West 9 (20.9)
Territory/Pacific Island Jurisdiction 5 (11.6)
Prevention and Public Health Funding to the immunization program 16 (37.2)
Collaboration with immunization program 35 (81.4)
Intervention typea
Provider education 28 (65.1)
Provider reminders 3 (7.0)
Provider assessment and feedback/quality improvement 10 (23.3)
Client reminders 8 (18.6)
Community education 37 (86.0)
School-based vaccination programs 5 (11.6)
Partnership building 10 (23.3)
Planning 19 (44.2)
Other 9 (20.9)
Multicomponent strategyb 29 (67.4)
aSome CCC programs reported more than one intervention type, or conducted planning activities before implementing interventions over the time 
period. Therefore, categories are not mutually-exclusive.
b
Two or more intervention types were used (e.g. community education along with client reminders)
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Table 2
HPV vaccine goal areas along with examples and associated objectives from Comprehensive Cancer Control 
(CCC) action plans, 2013 – 2016, n=43
Goals from President’s
Cancer Panel Report
Number of Programs,
(%)
Example
Intervention/activity
Associated
Objective from
CCC Action Plan
Address missed opportunities for 
vaccination
24 (55.8) Client reminders sent to patients seen 
at primary care clinics
“Increase the number of client 
reminders distributed to female and 
male adolescents ages 11–26, who 
are eligible patients at the seven 
primary care partner health clinics 
and are eligible for HPV 
vaccination…”
Peer-to-peer provider education on 
effective communication strategies to 
make strong vaccine recommendations 
and co administration of HPV vaccine 
with other adolescent vaccines
“Increase the number of providers 
completing the HPV peer-to-peer 
training curriculum…”
Maximize access to vaccination 
services
10 (23.3) Special school-based immunization 
clinics combined with HPV vaccine 
education at the local level
“Increase the number of cumulative 
HPV interventions implemented…”
HPV vaccine education and catch-up 
vaccination on college campuses 
through health clinics
“Increase the percent of vaccinations 
administered by an in state 
university's student health center…”
Increase vaccine acceptance 37 (86.0) Multi-year, ongoing communications 
campaign aimed at providers and 
parents
“Maintain the number of 
communications campaigns, aimed 
to increase awareness of HPV 
vaccination among parents and 
providers…”
School nurses trained in the 
prevention of cervical cancer and HPV 
vaccine
“Increase the number of educational 
workshops to promote human 
papillomavirus (HPV) 
vaccinations…”
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